

## Tomographic Imaging of Coronary Artery Disease using Computed Tomography versus Cardiac Magnetic Resonance: Concurring or Complementary to each Other?

Grigorios Korosoglou\*

GRN Hospital Weinheim, Department of Cardiology & Vascular Medicine, Weinheim, Germany

\*Corresponding author: Grigorios Korosoglou, GRN Hospital Weinheim, Department of Cardiology & Vascular Medicine, Roentgenstrasse 1, D-69469, Weinheim, Germany, Tel: + 49 6201 89 2142; Fax: +49 6201 89 2507; E-mail: [gkorosoglou@hotmail.com](mailto:gkorosoglou@hotmail.com)

Received date: June 10, 2016; Accepted date: June 10, 2016; Published date: June 29, 2016

Copyright: © 2016 Korosoglou G. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Keywords:** Coronary artery disease; Computed tomography; Cardiac magnetic resonance; Tomographic imaging


### Editorial

Currently, coronary artery disease due to atherosclerosis of the epicardial vessels remains the leading cause of death in Western societies. Traditionally, X-ray coronary angiography is regarded as the clinical gold standard technique for the diagnosis of the presence and extent of CAD. Current guidelines however, recommend the use of coronary angiography only in patients with  $\geq 85\%$  pre-test probability for obstructive CAD, where coronary intervention by PCI or CABG will be necessary [1]. In patients with intermediate pre-test probability between 15% and 85% on the other hand, non-invasive imaging techniques are preferable. In this regard, coronary computed tomography angiography (CCTA) and cardiac magnetic resonance (CMR) have emerged as promising non-invasive tomographic imaging modalities for the assessment of CAD.

The versatility of CMR provides the accurate assessment of myocardial function, perfusion, viability and if required strain and metabolism within a single examination and without radiation exposure for the patients. The accuracy of CMR is excellent due to its high spatial and temporal resolution and intrinsic blood-to-tissue contrast. In addition, its tomographic nature provides excellent comparability between perfusion and function in the corresponding

myocardial segments. The foremost strength of CMR is the evaluation of the functional relevance of CAD. Hereby, regional wall motion and perfusion abnormalities, during dobutamine or vasodilator stress, respectively precede the development of ST-segment depression and angina, enabling the precise detection of functionally significant CAD [2]. In addition, a meta-analysis which systematically analysed stress CMR studies conducted in  $\geq 11,500$  patients and with a mean follow-up duration of  $\geq 2.5$  yrs, found that patients with inducible ischemia by CMR exhibited a markedly higher risk for future cardiac events (odds ratio  $\sim 7.7$ ) [3]. Furthermore, the recent CE-MARC study for the first time in the current literature demonstrated the superior diagnostic accuracy of CMR compared to SPECT in a randomized manner [4]. An economic evaluation of this study, which used a decision analytic model to compare different diagnostic strategies in secondary care out-patients, showed that CMR is also a cost-effective strategy [5].

An example of the CMR scan of a young male patient with atypical angina, arterial hypertension and diabetes mellitus, but without history of vascular or coronary artery disease can be appreciated in Figure 1. Stress CMR during adenosine infusion exhibited inducible ischemia in the anterior-septal wall (a) during pharmacologic hyperemia, which was absent at baseline (b). Coronary angiography exhibited occlusion of the LAD (c), which was successfully treated by PCI and implantation of 3 drug-eluting coronary stents (d), resulting in complete resolution of clinical symptoms.



**Figure 1:** CMR images, demonstrating inducible perfusion defect of the anterior-septal LV wall during pharmacologic hyperemia with adenosine in (yellow arrow in a), which is not present at baseline (b). The patient underwent coronary angiography, where occlusion of the LAD was noticed (yellow arrow in c). Recanalization of the LAD was achieved by PCI and placement of 3 drug eluting stents with a good angiographic result (d).

CCTA on the other hand, provides non-invasive imaging of moving coronary arteries with sub-millimeter spatial resolution and high

signal-to-noise ratio. The strengths of CCTA encompass the visualization of coronary calcification, lumen narrowing and

atherosclerotic plaque composition. The great clinical strength of CCTA is its to 'rule-out' obstructive CAD in patients at intermediate risk, whereas in patients with high pre-test probability its clinical value may be limited [6]. Therefore, recent guidelines recommend the use of CCTA rather in patients at low intermediate pre-test probability for CAD (between 15% and 50%), especially in candidates with low and stable heart rate and with therefore expected good image quality and in the presence of adequate technology and local expertise [1].

The recent SCOT-HEART multicentre trial included over symptomatic 9,500 patients with suspected CAD, who were randomly assigned to standard care plus CCTA or standard care alone [7]. In this study, CCTA clarified the diagnosis of angina secondary to coronary heart disease, enabling targeting interventions. In addition, a trend for cardiac event reduction was observed in the CCTA arm, which however did not reach statistical significance. This reduction of cardiac events was possibly attributed to changes in medical treatment and to the identification of patients with left main or severe triple vessel disease, who were subsequently referred for coronary revascularization. Furthermore, the recently published EVINCI trial included 475 symptomatic patients with intermediate pre-test probability for CAD, who randomly underwent CCTA versus functional imaging by SPECT, stress echocardiography or CMR [8]. Hereby, CCTA exhibited significantly higher precision compared to functional tests for the detection of significant CAD, using X-ray coronary angiography in combination with FFR as the reference standard. In addition, recent studies suggested the ability of CCTA to calculate the functional significance of CAD with the so called CT-FFR, using invasive FFR measures as the reference standard [9]. If the implementation of this technique in the clinical realm is successful in the future, this will possibly increase the diagnostic accuracy of CCTA even in patients with high coronary calcification [10]. In this regard, CCTA may in that case represent a true valuable alternative to functional imaging in patients with moderate to high pre-test probability for CAD, who nowadays usually undergo non-invasive functional testing or invasive angiography in combination with FFR measures.

The cost-effectiveness of CCTA for the diagnostic work-up of patients with suspected CAD was systematically evaluated in a recent meta-analysis, where CCTA represented a cost-effective diagnostic strategy for the evaluation of symptomatic patients with stable and acute chest pain [11]. In the last decade several strategies have been developed to reduce radiation dose with CCTA, including dose modulation techniques, prospective ECG triggering, low-tube voltage CT imaging and iterative reconstruction algorithms. All these strategies, helped to reduce radiation exposure down to <1 mSv in most patients who currently undergo CCTA.

In conclusion, CCTA and CMR are in the meanwhile both clinically established techniques for the diagnosis of CAD. Current guidelines therefore encourage their liberal use as first choice modalities for the

diagnostic work-up of patients with low and intermediate likelihood for CAD. Technical developments with both tomographic imaging techniques CMR and CCTA will definitely help further increasing the precision of both techniques and reducing the radiation exposure with CCTA and will possibly define the most suited technique for the clinical imaging of CAD in the future.

## References

1. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, et al. (2013) 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J* 34: 2949-3003.
2. Nandalur KR, Dwamena BA, Choudhri AF, Nandalur MR, Carlos RC (2007) Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: a meta-analysis. *J Am Coll Cardiol* 50: 1343-1353.
3. Lipinski MJ, McVey CM, Berger JS, Kramer CM, Salerno M (2013) Prognostic value of stress cardiac magnetic resonance imaging in patients with known or suspected coronary artery disease: a systematic review and meta-analysis. *J Am Coll Cardiol* 62: 826-838.
4. Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, et al. (2012) Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. *Lancet* 379: 453-460.
5. Walker S, Girardin F, McKenna C, Ball SG, Nixon J, et al. (2013) Cost-effectiveness of cardiovascular magnetic resonance in the diagnosis of coronary heart disease: an economic evaluation using data from the CE-MARC study. *Heart* 99: 873-881.
6. Meijboom WB, van Mieghem CA, Mollet NR, Pugliese F, Weustink AC, et al. (2007) 64-slice computed tomography coronary angiography in patients with high, intermediate, or low pretest probability of significant coronary artery disease. *J Am Coll Cardiol* 50: 1469-1475.
7. (2015) SCOT-HEART investigators. CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial. *Lancet* : 2383-2391.
8. Neglia D, Rovai D, Caselli C, Pietila M, Teresinska A, et al. (2015) EVINCI Study Investigators. Detection of significant coronary artery disease by noninvasive anatomical and functional imaging. *Circ Cardiovasc Imaging* 8: e002179.
9. Norgaard BL, Leipsic J, Gaur S, Seneviratne S, Ko BS, et al. (2014) NXT Trial Study Group. Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps). *J Am Coll Cardiol* 63: 1145-1155.
10. Norgaard BL, Gaur S, Leipsic J, Ito H, Miyoshi T, et al. (2015) Influence of Coronary Calcification on the Diagnostic Performance of CT Angiography Derived FFR in Coronary Artery Disease: A Substudy of the NXT Trial. *JACC Cardiovasc Imaging* 9: 1045-1055.
11. Zeb I, Abbas N, Nasir K, Budoff MJ (2014) Coronary computed tomography as a cost-effective test strategy for coronary artery disease assessment - a systematic review. *Atherosclerosis* 234: 426-435.